4//SEC Filing
Rubin Jonathan 4
Accession 0001628280-25-007532
CIK 0001356576other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 8:20 PM ET
Size
19.6 KB
Accession
0001628280-25-007532
Insider Transaction Report
Form 4
Rubin Jonathan
SVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2025-02-21$39.15/sh−927$36,292→ 7,853 total - Award
Common Stock
2025-02-23+1,250→ 11,103 total - Disposition to Issuer
Restricted Stock Unit
2025-02-23−1,250→ 2,500 total→ Common Stock (1,250 underlying) - Award
Common Stock
2025-02-22+1,250→ 9,853 total - Disposition to Issuer
Restricted Stock Unit
2025-02-22−750→ 750 total→ Common Stock (750 underlying) - Exercise/Conversion
Common Stock
2025-02-21+1,875→ 8,780 total - Award
Common Stock
2025-02-22+750→ 8,603 total - Exercise/Conversion
Performance Share Units
2025-02-21−1,875→ 0 totalExercise: $0.00→ Common Stock (1,875 underlying) - Disposition to Issuer
Restricted Stock Unit
2025-02-22−1,250→ 3,750 total→ Common Stock (1,250 underlying)
Footnotes (7)
- [F1]Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
- [F2]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
- [F3]On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
- [F4]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- [F5]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
- [F6]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- [F7]These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Documents
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001836067
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 8:20 PM ET
- Size
- 19.6 KB